| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/03/2002 | WO2001045836A3 Molecules derived from mechanism based drug design |
| 01/03/2002 | WO2001045689A3 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 01/03/2002 | WO2001044260A3 Novel purines |
| 01/03/2002 | WO2001035935A3 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer |
| 01/03/2002 | WO2001032877A3 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 01/03/2002 | WO2001032843A3 Enhanced immune recognition of pathogenic cells by icsbp expression |
| 01/03/2002 | WO2001028587A3 Magnetic targeted carrier |
| 01/03/2002 | WO2000071563A3 Taccalonolide microtubule stabilizing agents |
| 01/03/2002 | WO2000061146A9 Camptothecin analogs and methods of preparation thereof |
| 01/03/2002 | US20020002292 C7 taxane derivatives and pharmaceutical compositions containing them |
| 01/03/2002 | US20020002269 Artemin, a neurotrophic factor |
| 01/03/2002 | US20020002197 Tropisetron, Fabesetron, Ramosetron and other drugs useful for treatment of a non-inflammatory local disease of the musculo-sceletal system, of a local irritation condition of a joint or tendom sheath or local manifestation |
| 01/03/2002 | US20020002191 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 01/03/2002 | US20020002188 Heterocyclic amides/imides as inhibitors of tumor necrosis factor alpha and nuclear factor kappa B and phosphodi-esterases III and IV; used to combat cachexia, endotoxic shock, retrovirus replication and asthma; antiinflammatory |
| 01/03/2002 | US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides |
| 01/03/2002 | US20020002173 E. g., 6-(3-chlorophenyl)-1,4-dihydro-4,4-dimethyl-2H-thieno-(2,3-d)(1,3)oxazine-2 -one; agonists and antagonists of the progesterone receptor; inducing contraception and treating or preventing benign or malignant neoplastic diseases |
| 01/03/2002 | US20020002168 Heterocyclic carboxamides |
| 01/03/2002 | US20020002162 Synergistic methods and compositions for treating cancer |
| 01/03/2002 | US20020002149 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| 01/03/2002 | US20020002138 For use in treatment of diseases associated with reduced levels of growth hormone |
| 01/03/2002 | US20020002134 PAI-2 conjugates for the treatment and imaging of cancer |
| 01/03/2002 | US20020002131 Providing exogenous antiangiogenic protein to endothelial cells associated with said tissue |
| 01/03/2002 | US20020001840 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 01/03/2002 | US20020001630 Angiogenesis inhibitor |
| 01/03/2002 | US20020001576 Medicaments containing allogenic activated-CD4+ cells as the main ingradient, which are attributable to an organ or bone marrow implant donor, have extreemly beneficial effect for preventing tumor and various infections |
| 01/03/2002 | US20020001567 Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| 01/03/2002 | US20020001566 Pharmaceuticals for the imaging of angiogenic disorders |
| 01/03/2002 | DE10029709A1 Verfahren zur Herstellung von dendritischen Strukturen A process for the preparation of dendritic structures |
| 01/03/2002 | DE10028204A1 Verfahren zur Auffindung von medizinisch wertvollen Wirkstoffen Method for identifying medically valuable active ingredients |
| 01/03/2002 | DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin |
| 01/03/2002 | CA2415873A1 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 01/03/2002 | CA2414512A1 Novel compounds possessing antibacterial, antifungal or antitumor activity |
| 01/03/2002 | CA2414401A1 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/03/2002 | CA2414210A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | CA2414150A1 Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof |
| 01/03/2002 | CA2414089A1 Improvements in and relating to chromophores |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413579A1 Methods and compounds for inhibiting mrp1 |
| 01/03/2002 | CA2413543A1 Human papilloma virus treatment |
| 01/03/2002 | CA2413417A1 Selective androgen receptor modulators and methods for their identification, design and use |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2412637A1 Replication deficient adenoviral tnf vector |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/03/2002 | CA2412612A1 Eg-vegf nucleic acids and polypeptides and methods of use |
| 01/03/2002 | CA2412610A1 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | CA2412592A1 Substituted quinazoline derivatives and their use as inhibitors |
| 01/03/2002 | CA2412582A1 Dds compound and process for the preparation thereof |
| 01/03/2002 | CA2412559A1 Polycyclic xanthones as antibiotics |
| 01/03/2002 | CA2412535A1 Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride |
| 01/03/2002 | CA2412256A1 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | CA2412211A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2412089A1 Prostase protein vaccine comprising derivatised thiol residues and methods for producing said antigen |
| 01/03/2002 | CA2412084A1 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
| 01/03/2002 | CA2411545A1 Tripeptide prodrug compounds |
| 01/03/2002 | CA2411157A1 Benzodiazepines as inhibitors of hpv e1 helicase |
| 01/03/2002 | CA2409408A1 Modulation of chromosome function by chromatin remodeling agents |
| 01/03/2002 | CA2381338A1 Human lyases |
| 01/03/2002 | CA2381241A1 Truncated egf receptor |
| 01/02/2002 | EP1167972A2 Enzyme catalyzed therapeutic agents |
| 01/02/2002 | EP1167389A1 Antibodies against the protein SEMP1, methods for their production and uses thereof |
| 01/02/2002 | EP1167386A1 Canine and feline melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate |
| 01/02/2002 | EP1167384A1 HVEGF Receptor as Vascular endothelial cell growth factor antagonists |
| 01/02/2002 | EP1167379A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167378A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167377A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167366A1 Amine derivatives |
| 01/02/2002 | EP1167364A1 Benzopyran-containing compounds and prodrug forms thereof |
| 01/02/2002 | EP1167357A1 Alpha-substituted carboxylic acid derivatives |
| 01/02/2002 | EP1166795A2 Skin cancer preventive agent containing sericin |
| 01/02/2002 | EP1166789A2 Arsenolite containing angiogenesis inhibitor |
| 01/02/2002 | EP1166788A1 Remedies for joint diseases |
| 01/02/2002 | EP1166786A1 Medicinal compositions |
| 01/02/2002 | EP1166781A1 Proteasome inhibitors |
| 01/02/2002 | EP1166775A2 Targeted liposome gene delivery |
| 01/02/2002 | EP1165828A1 50 human secreted proteins |
| 01/02/2002 | EP1165827A1 45 human secreted proteins |
| 01/02/2002 | EP1165818A2 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 01/02/2002 | EP1165812A2 Protozoan expression system |
| 01/02/2002 | EP1165805A1 Dsp-2 dual-specificity map kinase phosphatase |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165788A2 Molecules of the immune system |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165781A2 Protease resistant flint analogs |
| 01/02/2002 | EP1165778A2 Casb618 polynucleotides and polypeptides and their use |
| 01/02/2002 | EP1165777A2 Genes encoding human potassium channel proteins |
| 01/02/2002 | EP1165774A2 Casb619 involved in colon cancers |
| 01/02/2002 | EP1165616A1 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases |
| 01/02/2002 | EP1165615A2 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE |
| 01/02/2002 | EP1165605A1 Androgen-induced suppressor of cell proliferation and uses thereof |
| 01/02/2002 | EP1165602A1 49 human secreted proteins |
| 01/02/2002 | EP1165601A2 Prodrugs of thrombin inhibitors |
| 01/02/2002 | EP1165594A1 Antisense oligonucleotide modulation of stat3 expression |
| 01/02/2002 | EP1165591A1 47 human secreted proteins |
| 01/02/2002 | EP1165587A1 50 human secreted proteins |
| 01/02/2002 | EP1165586A1 TCL-1b GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS |
| 01/02/2002 | EP1165576A1 Process for preparing amine platinum complexes |
| 01/02/2002 | EP1165570A2 Novel phosphorus-containing prodrugs |
| 01/02/2002 | EP1165566A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 01/02/2002 | EP1165565A1 Optically pure camptothecin analogues |
| 01/02/2002 | EP1165562A1 Cyclic substituted fused pyrrolocarbazoles and isoindolones |